(Q43841306)

27 November 2017

title

Progress in CLL, chemotherapy, antibodies and transplantation (English)

1 reference

27 November 2017

Keating MJ

1

1 reference

27 November 2017

publication date

1 November 2001

1 reference

Biomedicine and Pharmacotherapy

27 November 2017

published in

1 reference

27 November 2017

volume

55

1 reference

27 November 2017

issue

9-10

1 reference

27 November 2017

page(s)

524-528

1 reference

The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900139-1

7 January 2021

10.1016/S0753-3322(01)00139-1

Identifiers

DOI

1 reference

27 November 2017

1 reference